0UGB Stock Chart & Stats
C$12.74
C$0.00(0.00%)
At close: 4:00 PM EDT
C$12.74
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$7.45 - C$12.74
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
C$9.22M
Enterprise ValueC$1.56
Total Cash (Recent Filing)C$5.27M
Total Debt (Recent Filing)C$1.95M
Price to Earnings (P/E)―
Beta-0.10
Next Earnings
Nov 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.03
Shares Outstanding996,394
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.57
Price to Sales (P/S)0.29
P/FCF Ratio-0.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Gross MarginThe higher gross margin indicates improved economics on current revenue and may provide a stronger base for future operating leverage. If maintained, this improvement can help the company convert revenue stabilization into narrower losses and increase the durability of its therapeutic commercialization model.
Narrowing Net LossesSubstantial loss reduction shows that the company has made progress controlling its earnings deficit, even though it remains unprofitable. Continued improvement would extend its financial runway and could reduce the scale of future funding pressure as the business develops its products.
Manageable LeverageA relatively conservative capital structure gives COSCIENS more financial flexibility than a heavily leveraged balance sheet would provide. Lower debt exposure can reduce financing strain and leave greater capacity to direct resources toward product development and commercialization over the next several quarters.
Bears Say
Persistent UnprofitabilityThe company remains deeply unprofitable despite narrowing losses, so its current revenue base is not yet sufficient to support the full cost structure. This limits internal funding capacity and means future progress still depends on achieving further operating improvement before earnings can become sustainable.
Continued Cash BurnNegative operating and free cash flow show that the business continues to consume cash rather than finance operations internally. Persistent cash burn can constrain investment in therapeutic development and increase the importance of additional financing or further cost reductions over the medium term.
Weak Revenue TrendThe reported negative revenue-growth trend indicates that commercial scale remains fragile, even though the latest TTM figures show some stabilization. Without sustained top-line expansion, margin gains and cost reductions may not be enough to produce durable profitability or support broader product investment.
COSCIENS Biopharma News
0UGB FAQ
What was COSCIENS Biopharma’s price range in the past 12 months?
COSCIENS Biopharma lowest share price was C$7.45 and its highest was C$12.74 in the past 12 months.
What is COSCIENS Biopharma’s market cap?
COSCIENS Biopharma’s market cap is C$9.22M.
When is COSCIENS Biopharma’s upcoming earnings report date?
COSCIENS Biopharma’s upcoming earnings report date is Nov 17, 2026 which is in 47 days.
How were COSCIENS Biopharma’s earnings last quarter?
COSCIENS Biopharma released its earnings results on Aug 11, 2026. The company reported -C$0.267 earnings per share for the quarter.
Is COSCIENS Biopharma overvalued?
According to Wall Street analysts COSCIENS Biopharma’s price is currently Overvalued.
Does COSCIENS Biopharma pay dividends?
COSCIENS Biopharma does not currently pay dividends.
What is COSCIENS Biopharma’s EPS estimate?
COSCIENS Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COSCIENS Biopharma have?
COSCIENS Biopharma has 996,394 shares outstanding.
What happened to COSCIENS Biopharma’s price movement after its last earnings report?
COSCIENS Biopharma reported an EPS of -C$0.267 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of COSCIENS Biopharma?
Currently, no hedge funds are holding shares in GB:0UGB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSCIENS Biopharma
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
Technical Analysis
BetterLife Pharma
―
PharmaTher Holdings Ltd
―
Glow LifeTech
―
Marvel Biosciences Corp
―
PharmAla Biotech Holdings, Inc.
―